Human Cytochromes P450: Evolution and cDNA-Directed Expression

by Frank J. Gonzalez and Harry V. Gelboin

As the first step in the process of carcinogenesis, most chemical carcinogens require metabolic activation by cytochromes P450 for conversion to highly reactive electrophiles that bind covalently to DNA. Studies in rodents suggest that low or high levels of expression of a single P450 can determine susceptibility or resistance to chemically induced cancer. Although rodent systems have been used to explore the molecular basis of chemical carcinogenesis and to identify chemicals capable of damaging genes and causing cancer, it has been understood that marked species differences exist in the expression, regulation, and catalytic activities of different P450s. Thus, large efforts are underway to study the catalytic activities of human P450s directly by expression of their cDNAs in cultured cells. Two systems are being used: a) transient high-level P450 production in HepG2 cells for analysis of catalytic activities, and b) stable expression in human B-lymphoblastoid cells to study promutagen and procarcinogen activation. These studies define the relative contributions of individual P450 forms to the activation of various chemical carcinogens. The B-lymphoblastoid cDNA expression system can also be used to determine whether a chemical will be hazardous or toxic to humans. The most intriguing aspects of P450s are the occurrence of human genetic polymorphisms in P450 expression, which could be a risk factor for chemical carcinogenesis. The best-studied P450 genetic polymorphism is the debrisoquine/sartepine polymorphism which is due to mutant CYP2D6 alleles. Four mutant alleles have been characterized that account for most of the defective CYP2D6 genes in Caucasians. These can be detected by polymerase chain reaction assays. The expression of other P450s is currently being studied in human tissue specimens to determine whether functional polymorphisms exist with other P450 forms.

Properties, Organization, and Nomenclature of Cytochromes P450

As a group, cytochromes P450 (P450) range in size from about 48 to 60 kDa and contain a single molecule of noncovalently bound heme. All P450s use O₂ and electrons, usually from NADPH, to oxidize substrates by production of an activated oxygen. The region of the P450 primary sequence that contains the thiolate fifth ligand to the heme iron (1) is highly conserved (2). This sequence of about 26 residues could be considered a “fingerprint” for a P450 protein.

Three general classes of P450s exist: a) soluble forms with high substrate specificity found in bacteria; b) those involved in highly specific steroid hydroxylations, some of which are located in the inner mitochondrial membrane (encoded by nuclear DNA); and c) those bound to the endoplasmic reticulum of the cell, which, by and large, have broad substrate specificities. Some of these P450s activate chemical carcinogens to their proximate electrophilic forms which can bind covalently to DNA.

P450s have been organized on the basis of similarities in protein sequence, and a nomenclature system has been developed (3). The “P450 superfamily” is subdivided into families; individual P450s within a family are defined as having ≤40% sequence similarity with a P450 in any other family. Families are further divided into subfamilies: all P450s within a subfamily are >55% similar in sequence.

P450s are named using the root symbol CYP (Cytochrome P450), followed by an Arabic numeral designating the family number, a letter denoting the subfamily, and another Arabic numeral representing the individual gene. Thus, CYP1A1 is P450 form 1 in the A subfamily of family 1. Names of genes are written in italics, CYP1A1. It should be emphasized that the nomenclature system is based solely on sequence similarity among P450s and does not indicate the properties or function of individual P450s. Circumstantially, however, the steroidogenic P450s fall into families distinct from those of the foreign compound metabolizing enzymes. The latter fall almost exclusively into mammalian families, CYP1, CYP2, CYP3, and CYP4.

Because of the diverse catalytic activities of the foreign compound metabolizing P450s, it has been difficult to identify orthologous P450 counterparts among species (an orthologous P450 gene in two species is one that shared a common ancestor before evolutionary divergence of the two species); this has complicated P450 nomenclature. Of the foreign compound metabolizing P450s, only CYP1A1 and CYP1A2 have unequivocal orthologous counterparts.

1Laboratory of Molecular Carcinogenesis, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892.
Address reprint requests to F. J. Gonzalez, Building 37, Room 3E24, National Institutes of Health, Bethesda, MD 20892.
in all animal species examined. Individual P450s within a subfamily are designated by different numbers: for example, rats possess CYP2D1 through CYP2D5, humans CYP2D6 through CYP2D8, and mice CYP2D9 through CYP2D13.

**Evolution of P450s and Species Differences**

P450s are believed to have evolved from a common ancestor about 3 billion years ago (4). The earliest P450s probably existed to metabolize steroids such as cholesterol in order to maintain membrane integrity, and several P450s continued through the course of evolution to function in steroid biosynthesis and metabolism. Only more recently (during the last 100–500 million years) have P450s taken on the role of ridding the organism of foreign compounds. Numerous gene duplications have occurred during the past 200 million years; most importantly, new P450 genes were formed in certain species and some lost in other species. This process is best illustrated by examining the complexity of the CYP2D genes in rodents and humans (5). Rats and mice possess five genes, all of which appear to be normal, whereas humans have one active gene and two pseudogenes. The rodent genes have also undergone numerous "homogenizing" gene conversion events, so that no orthologous counterpart of any single rat gene can be identified in mice. Other events, in addition to gene conversion, that occur in a species-specific manner, possibly due to environmental influences, have resulted in catalytic activities and regulatory circuits that can be unique to a given animal.

It is not currently understood what environmental factors give rise to the battery of P450s in an animal or, at a more basic level, how and why foreign compound metabolizing P450s have arisen. One possibility is that these enzymes evolved as a defense against toxins found in the food chain, particularly in plants, in which a large number of toxins has been developed, probably as a defense against predators. New P450s thus appeared in response to plant toxins or new plant varieties or as a means of exploiting new sources of vegetation. Conversely, when a plant source is no longer available, certain P450s might disappear from the gene pool. Indeed, the entire CYP2D locus appears to be vanishing in humans (5).

The consequences of P450 evolution are species differences and genetic polymorphisms. Species differences in P450s have meant that better focus and direct examination of human enzymes and less reliance on data from rodents are required to predict the adverse effects of chemicals. P450 polymorphisms have had a direct impact on the development of drugs in the pharmaceutical industry, because certain established P450 forms clearly exhibit genetic differences and are known to metabolize and gen-

| P450    | Tissue | Rodent ortholog | cDNA expression | Substrates* |
|---------|--------|-----------------|-----------------|------------|
| CYP1A1  | Many   | Yes             | Yeast (7)       | Benzo(a)pyrene |
|         |        |                 | Vaccinia (8)    | 2-Acetylaminofluorene |
|         |        |                 | Lymphoblastoid (9) | Aflatoxin B1 |
| CYP1A2  | Liver  | Yes             | Yeast (7)       | Heterocyclic arylamines |
|         |        |                 | Vaccinia (10)   | Coumarin |
|         |        |                 | Lymphoblastoid (9) | Aflatoxin B1 |
| CYP2A6  | Liver  | Yes             | Yeast (13)      | N-Nitrosodiethylamine |
|         | Lung   |                 | Vaccinia (11)   | 7-Ethoxycoumarin |
|         |        |                 | Lymphoblastoid (9) | Aflatoxin B1 |
| CYP2B7  | Liver  | Yes             | Yeast (13)      | Tolbutamide |
|         |        |                 | Vaccinia (12)   | Tolbutamide |
| CYP2C8  | Liver  | Yes             | Yeast (13)      | Tolbutamide |
| CYP2C9  | Liver  | Yes             | Yeast (13)      | Tolbutamide |
| CYP2C10 | Liver  | Yes             | Yeast (13)      | Tolbutamide |
| CYP2C17 | Liver  | Yes             | Yeast (13)      | Tolbutamide |
| CYP2C18 | Liver  | Yes             | Yeast (13)      | Tolbutamide |
| CYP2C19 |Liver   | Yes             | Yeast (13)      | Tolbutamide |
| CYP2D6  | Liver  | Yes             | Yeast (13)      | Tolbutamide |
|         | Kidney |                 | Yeast (13)      | Tolbutamide |
| CYP2E1  | Liver  | Yes             | Yeast (13)      | Tolbutamide |
| CYP2F1  | Lung   | Yes             | Yeast (13)      | Tolbutamide |
| CYP3A3  | Liver  | Yes             | Yeast (13)      | Tolbutamide |
| CYP3A4  | Liver  | Yes             | Yeast (13)      | Tolbutamide |
| CYP3A5  | Liver  | Yes             | Yeast (13)      | Tolbutamide |
| CYP4B1  | Lung   | Yes             | Yeast (13)      | Tolbutamide |

*Partial list of preferred substrates for each P450; a more complete compilation is given by Guengerich and Shimada (6).

* CYP1A1 is not appreciably expressed in the absence of inducers such as polycyclic aromatic hydrocarbons or dioxins.

* Formerly called CYP2A3.

* COS is a monkey-kidney-derived cell line.
generally inactivate therapeutic agents. The extent of P450 polymorphisms in humans is also being evaluated with a view to diagnostic analysis of mutant human P450 genes, to investigate whether the presence or absence of a P450 involved in activation or inactivation of a carcinogen results in an increased risk of or protection against cancer.

**cDNA Expression of Human P450s and Risk Assessment**

Human P450s can be studied directly after isolation from tissues such as liver by reconstitution with NADPH-P450 oxidoreductase and analysis of their catalytic activities in the tissue or in microsomal extracts, using immunochemical approaches. These types of investigations have led to determination of substrate specificities of individual P450 forms and the role of specific P450s in total liver microsomal metabolism of specific procarcinogens (6).

cDNA expression has also been used to study human P450 catalytic activities. It has been relatively straightforward to isolate human P450 cDNAs from cDNA libraries constructed from liver and lung tissue RNA, using antibodies and cDNA probes against different rodent P450 forms. Human P450s that have been isolated to date, their tissue-specific expression, whether a rodent counterpart exists, and a typical substrate are listed in Table 1. Two cDNAs, CYP1A1 and CYP1A2, were isolated from human cells and liver libraries, respectively, and apparently share enzymatic properties with their rodent counterparts. At least nine cDNAs that encode active enzymes in the CYP2 family have also been isolated. One form, CYP2F1, appears to be expressed preferentially in extrahepatic tissues. Of these cDNA-expressed forms, only CYP2E1 exhibits catalytic activities that are similar to those of rat and rabbit CYP2E1. Four distinct CYP3A P450 cDNAs were isolated from human liver, one of which is expressed only in the fetus. Only two CYP3A P450s have been described in rat, and one in rabbit. All CYP3A P450s exhibit testosterone 6β-hydroxylase activities, but activities toward other substrates may differ. To date, no P450 has been demonstrated in the CYP4 family, although they are known to exist.

Human cDNA-expressed P450s can be examined for their abilities to activate promutagens and procarcinogens using three protocols: a) direct assay of active metabolites by analytical separation; b) an Ames test assay in which human P450s are substituted for the standard Aroclor-induced rat liver extracts; and c) in-situ DNA binding assays in cells that express human P450s.

The Ames test has been used to evaluate the role of different human P450s in the activation of the cooked food-derived mutagen, 2-amino-3-methylimidazo [4,5-F]quinoline (IQ), by cDNA-expressed human liver P450 (20). CYP1A2, an enzyme expressed constitutively in liver and not in extrahepatic tissues, was the most active, followed by P450s in the CYP3 family which are expressed in several extrahepatic tissues. Food mutagens are typically carcinogens in nonliver tissue (27), although they are potent hepatocarcinogens in nonhuman primates (28). These compounds might be activated in the liver extrahepatically by CYP1A2 and the CYP3 P450s, respectively.

Aflatoxin B1 activation was measured by DNA binding in situ in an experiment in which cells that express different forms of human P450 in culture were incubated with radio-labeled carcinogens; DNA-bound carcinogen was then determined (29). Five human P450 forms were found to catalyze DNA binding, while another seven forms were inactive. These five forms were also active in aflatoxin B1 mutagenesis, as measured in the Ames test; however, the conditions of the experiment did not distinguish those P450s with high affinity for aflatoxin B1 from low-affinity forms.

Metabolic activation by human P450s of a rodent and ruminant pneumotoxin, 4-ipomeanol, was also evaluated (30). Surprisingly, the primary human lung P450s CYP2F1 and CYP4B1 were unable to activate this compound; in contrast, rabbit CYP4B1 and human CYP1A2, a nonpulmonary P450, were active. These data indicate a marked species difference in the catalytic activity of one P450.

Human P450s have also been expressed using a B-lymphoblastoid cell line, AH1-1, with herpes virus-based vectors. A number of P450s have been accurately expressed using this system, including CYP1A2, CYP2A6, CYP2D6, CYP2E1, and CYP3A4 (Table 1). This expressed system differs from that of V. carinava, since the P450s are stably expressed. AH1-1 cells are especially useful for expressing P450s because they were originally developed as a eukaryote mutagen testing system (31).

Metabolic activation of aflatoxin B1 was also studied using cell lines that express individual P450s (9). Cells were assayed for toxicity and mutagenicity at the hypoxanthine guanine phosphoribosyl transferase (hprt) locus. CYP1A2-expressing cells were the most sensitive to the toxicity and mutagenicity of aflatoxin B1; as little as 10 ng/mL of the carcinogen in the medium produced a significant response. CYP3A4-expressing cells were also sensitive to aflatoxin B1, although about 5- to 10-fold less than CYP1A2-containing cells. Cells that express CYP2A6 were the least sensitive, and cells with no expressed human P450 were resistant to the compound at a level of 1 μg/mL. These data suggest that CYP1A2 has the highest activation activity for aflatoxin B1, and it is probably the P450 form that activates the carcinogen under ordinary conditions of human exposure.

In a separate experiment, CYP2E1 and CYP2A6 were compared for their ability to activate the low-molecular-weight nitrosamines N-nitosodimethylamine and N-nitrosodiethyamine (21). Surprisingly, considering the structural similarities of these two nitrosamines, cells that express either P450 were sensitive to both chemicals but CYP2A6-expressing cells were considerably more sensitive to the toxicity and mutagenicity of N-nitrosodimethylamine and CYP2E1-expressing cells were more sensitive to N-nitrosodiethyamine.

Cells suitable for analyzing diverse classes of carcinogens and mutagens should simultaneously express multiple P450s. This has been accomplished to a degree by inserting four P450 cDNAs and epoxide hydratase cDNA
into a cell line. These cells, designated MCL-5, are responsive to small nitrosamines, polycyclic aromatic hydrocarbons, and aflatoxin B1 (32) and are potential prototypes of cells that could be used to test unknown compounds for carcinogeticity and mutagenicity.

**Interindividual Differences in P450 Expression and Cancer Susceptibility**

Early studies in clinical pharmacology established that marked interindividual differences in P450 expression exist as a human polymorphism. The clearest examples is the debrisoquine/sparfaine drug oxidation genetic polymorphism, in which 75% of Caucasians possess two copies of a mutant CYP2D6 gene and thus cannot metabolize debrisoquine and a growing number of other clinically used drugs (33). Almost all mutant genes can be diagnosed by polymerase chain reaction analysis of leukocyte DNA. Another drug oxidation polymorphism, associated with S-mephenytoin and involving a P450 in the CYP2C subfamily, exists, but it has not been elucidated at the molecular level.

Epidemiological evidence shows that CYP2D6 expression is associated with risk for smoking-associated nonadenocarcinoma of the lung (34). CYP2D6 is capable of metabolically activating the tobacco smoke-specific nitrosamine 4-[(N-nitrosomethyl)amino]-1-(3-pyridyl)-1-butanone (NNK) (18); however, several other P450s are also capable of activating this compound. Thus, the precise biochemical basis of the association between CYP2D6 and cancer is still unclear.

The question remains whether interindividual differences in levels of expression of other known carcinogen-activating P450s are associated with increased cancer risk. Marked differences exist in the levels of expression of CYP1A2 (35-37), CYP2A6 (10), CYP2B6 (11), CYP2E1 (38), and the CYP3A P450s (23), as detected by western immunoblot and northern blot analysis of protein and mRNA isolated from human liver specimens; there is also a large degree of variation in the expression of CYP1A1 mRNA in lung samples from smokers and nonsmokers. In order to establish whether expression of a P450 is associated with increased cancer risk, however, cohort and prospective epidemiological surveys must be conducted. These will be possible only when accurate, noninvasive assays can be provided for measuring P450 form-specific activities in humans. Several candidate compounds that can be used in this capacity have been proposed (6) but have yet to be used in cancer epidemiological studies.

This manuscript was presented at the Conference on Biomonitoring and Susceptibility Markers in Human Cancer: Applications in Molecular Epidemiology and Risk Assessment that was held in Kailua-Kona, Hawaii, 26 October–1 November 1991.

**REFERENCES**

1. White, R. E., and Coon, M. J. Oxygen activation by cytochrome P-450. Annu. Rev. Biochem. 48: 315–356 (1980).
2. Gonzalez, F. J. The molecular biology of cytochrome P450s. Pharmacol. Rev. 40: 243–298 (1988).
3. Nebert, D. W., Nelson, D. R., Coon, M. J., Estabrook, R. W., Feyereisen, R., Fujii-Kuriyama, Y., Gonzalez, F. J., Guengerich, F. P., Gunsalus, I. C., Johnson, E. F., Lopez, J. C., Sato, R., Waterman, M. R., and Waxman, D. J. The P450 superfamily: update on new sequences, gene mapping and recommended nomenclature. DNA Cell Biol. 10: 1–14 (1991).
4. Nelson, D. R., and Strobel, H. W. Evolution of cytochrome P-450 proteins. Mol. Biol. Evol. 4: 572–593 (1987).
5. Gonzalez, F. J., and Nebert, D. W. Evolution of the P450 gene superfamily animal plant “warfare,” molecular drive and human differences in drug oxidation. Trends Genet. 6: 182–186 (1990).
6. Guengerich, F. P., and Shimada, T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem. Res. Toxicol. 4: 391–407 (1991).
7. Eustiger, H.-P., Sengstag, C., Meyer, U. A., Hinne, A., and Würgler, F. E. Constitutive and inducible expression of human cytochrome P450IA1 in yeast Schizosaccharomyces cerevisiae: an alternative enzyme source for in vitro studies. Biochem. Biophys. Res. Commun. 172: 737–744 (1990).
8. Aoyama, T., Gonzalez, F. J., and Gelboin, H. V. Human cDNA-expressed cytochrome P450 IA2: mutagen activation and substrate specificity. Mol. Carcinog. 2: 40–46 (1989).
9. Crespi, C., Penman, B. W., Steinel, D. T., Gelboin, H. V., and Gonzalez, F. J. The development of a human cell line stably expressing human CYP3A4: role in the metabolic activation of aflatoxin B1, and comparison to CYP1A2 and CYP2A3. Carcinogenesis 12: 355–359 (1991).
10. Yamano, S., Tatsuno, J., and Gonzalez, F. J. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 29: 1322–1329 (1990).
11. Yamano, S., Nhamhoro, P. T., Aoyama, T., Meyer, U. A., Inaba, T., Kalow, W., Gelboin, H. V., McBride, O. W., and Gonzalez, F. J. cDNA Cloning and sequencing and cDNA-directed expression of human P450 IB1: identification of a normal and two variant cDNAs derived from the CYP2B7 locus on chromosome 19 and differential expression of one of the mRNAs in human liver. Biochemistry 28: 7340–7348 (1989).
12. Belling, M. V., Aoyama, T., Gonzalez, F. J., and Meyer, U. A. Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. J. Pharmacol. Exp. Ther. 252: 442–447 (1990).
13. Brian, W. R., Srivastava, P. D., Umbenhauer, D. R., Lloyd, R. S., and Guengerich, F. P. Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. Biochemistry 28: 4993–4999 (1989).
14. Romkes, M., Faletto, M. B., Blaisdell, J. A., Raucy, J. L., and Goldstein, J. A. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P45011C subfamily. Biochemistry 30: 3247–3255 (1991).
15. Furuta, H., Meyer, U. A., Gelboin, H. V., and Gonzalez, F. J. Polymerase chain reaction-directed identification, cloning and quantification of human CYP2C18 mRNA. Mol. Pharmacol. 40: 375–382 (1991).
16. Gonzalez, F. J., Skoda, R. C., Kimura, S., Umeno, M., Zanger, U. M., Nebert, D. W., Gelboin, H. V., Hardwick, J. P., and Meyer, U. A. Molecular characterization of the common human deficiency in polymorphism of debrisoquine and other drugs. Nature 351: 442–445 (1990).
17. Tyndale, R., Aoyama, T., Broly, F., Matsunaga, T., Inaba, T., Kalow, W., Gelboin, H. V., Meyer, U. A., and Gonzalez, F. J. Identification of a new CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype. Pharmacogenetics 1: 26–32 (1991).
18. Crespi, C. L., Penman, B. W., Gelboin, H. V., and Gonzalez, F. J. A tobacco smoke-derived nitrosamine, 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone (NNK) is activated by the polymorphic human cytochrome P4502D6 (CYP2D6). Carcinogenesis 12: 1197–1201 (1991).
19. Umeno, M., McBride, O. W., Yang, C. S., Gelboin, H. V., and Gonzalez, F. J. Human ethanol-inducible P4501E1: complete gene sequence, promoter characterization, chromosome mapping, regulation, and cDNA directed expression. Biochemistry 27: 9006–9013 (1988).
20. Aoyama, T., Gelboin, H. V., and Gonzalez, F. J. Mutagenic activation of 2-amino-3-methylimidazo[4,5-f] quinoline (IQ) by cDNA-expressed human liver P450. Cancer Res. 50: 2060–2067 (1990).
21. Crespi, C. L., Penman, B., Leake, J. A. E., Arlottto, M., Stark, A., Turner, T., Steinel, D., Rudo, K., Davies, R. L., and Langenbach, R.
Human cytochrome P450IIIA3 cDNA sequence, role of the enzyme in the metabolic activation of promutagen: comparison to nitrosamine activation by human cytochrome P450IIE1. Carcinogenesis 11: 1293–1300 (1990).

22. Nhamburo, P. T., Kimura, S., McBride, O. W., Kozak, C. A., Gelboin, H. V., and Gonzalez, F. J. The human CYP2F subfamily: identification of a cDNA coding for a new cytochrome P450 expressed in lung, cDNA-directed expression and chromosome mapping. Biochemistry 29: 5491–5499 (1990).

23. Aoyama, T., Yamano, S., Waxman, D. J., Meyer, U. A., Fisher, V., Lapenson, D. P., Tyndale, R., Inaba, T., Kalow, W., Gelboin, H. V., and Gonzalez, F. J. Cytochrome P450 hPCN3, a novel P450 IIIA gene product that is differentially expressed in adult human liver: cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J. Biol. Chem. 264: 10388–10395 (1989).

24. Gonzalez, F. J., Schmid, B., Uneno, M., McBride, O. W., Hardwick, J. P., Meyer, U. A., Gelboin, H. V., and Idle, J. R. Sequence, chromosome localization and direct evidence through cDNA expression that P-450PCN1 is nifedipine oxidase. DNA 7: 79–86 (1988).

25. Brian, W. R., Sari, M.-A., Iwasaki, M., Shimada, T., Kaminsky, L. S., and Guzelian, P. P. Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae. Biochemistry 29: 11280–11282 (1990).

26. Nhamburo, P. T., Gonzalez, F. J., McBride, O. W., Gelboin, H. V., and Kimura, S. Identification of a new P450 expressed in human lung: complete cDNA sequence, cDNA-directed expression and chromosome mapping. Biochemistry 28: 8060–8065 (1989).

27. Sugimura, T. Carcinogenicity of mutagenic heterocyclic amines formed during the cooking process. Mutat. Res. 156: 33–41 (1985).

28. Adamson, R. H. Induction of hepatocellular carcinomas in nonhuman primates by chemical carcinogens. Cancer Detect. Prev. 14: 215–219 (1989).

29. Aoyama, T., Yamano, S., Guzelian, P. S., Gelboin, H. V., and Gonzalez, F. J. Five forms of vaccinia virus expressed human hepatic cytochrome P450 metabolically activate aflatoxin B1. Proc. Natl. Acad. Sci. USA 87: 4790–4793 (1990).

30. Czerwinski, M., McLemore, T. L., Philpot, R. M., Nhamburo, P. T., Korzekwa, K., Gelboin, H. V., and Gonzalez, F. J. Metabolic activation of 4-ijenoal by cDNA-expressed human cytochrome P450: evidence for species-specific metabolism. Cancer Res. 51: 4630–4642 (1991).

31. Crespi, C. L., and Thilly, W. G. Assay for gene mutation in a lymphoid line AHH-1 competent for xenobiotic metabolism. Mutat. Res. 128: 221–230 (1986).

32. Crespi, C. L., Gonzalez, F. J., Steinbel, D. T., Turner, T. R., Gelboin, H. V., Penman, B. W., and Langenbach, R. A metabolically competent cell line expressing 5 cDNAs encoding procarcinogen-activating enzymes: application to mutagen testing. Chem. Res. Toxicol. 4: 566–572 (1991).

33. Gonzalez, F. J., and Meyer, U. A. Molecular genetics of the debrisoquine/sparteine polymorphism. Clin. Pharmacol. Ther. 50: 233–238 (1991).

34. Caporaso, N. The relevance of metabolic polymorphisms to human carcinogenesis: evaluation of epidemiologic evidence. Pharmacogenetics 1: 4–19 (1991).

35. Wrighton, S. A., Campanile, C., Thomas, P. E., Maines, S. L., Watkins, P. B., Parker, G., Mendez-Picon, G., Haniu, M., Shively, J. E., Leven, W., and Guzelian, P. S. Identification of a human liver cytochrome P-450 homologous to the major isosafrole-inducible cytochrome P-450 in the rat. Mol. Pharmacol. 29: 405–410 (1986).

36. Distlerath, L. M., Belley, P. E. B., Martin, M. V., Davis, G. G., Wilkinson, G. R., and Guengerich, F. P. Purification and characterization of the human liver cytochromes P-450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolisms. J. Biol. Chem. 260: 9057–9067 (1985).

37. McMans, M. E., Stupans, I., Ioannini, B., Burgess, W., Robson, R. A., and Birkett, D. J. Identification and quantitation in human liver of cytochromes P-450 analogous to rabbit cytochromes P-450 analogous to rabbit cytochromes P-450 forms 4 and 6. Xenobiotica 18: 207–216 (1988).

38. Yoo, Y.-S. H., Guengerich, F. P., and Yang, C. S. Metabolism of N-nitrosodialkylamines by human liver microsomes. Cancer Res. 48: 1496–1504 (1988).